Ewing sarcoma

Changed by Francis Deng, 18 Jan 2020

Updates to Article Attributes

Body was changed:

Ewing sarcomas are the second most common malignant primary bone tumours of childhood after osteosarcoma, typically arising from medullary cavity with invasion of the Haversian system. They usually present as moth-eaten destructive permeative lucent lesions in the shaft of long bones with large soft tissue component without osteoid matrix and typical onion skin periostitis. It may also involve flat bones and appears sclerotic in up to 30% of cases.

Epidemiology

Ewing sarcoma typically occurs in children and adolescents between 10 and 20 years of age (95% between 4 and 25 years of age), and has a slight male predilection (M:F 1.5:1) 1,2.

The Ewing sarcoma family of tumors primarily occurs in white patients and is uncommon in blacks and Asians. In the United States, the incidence in Asians/Pacific Islanders is about one-half that in Caucasians, while the incidence among African Americans is one-ninth that in Caucasians 12.

Clinical presentation

Presentation is non-specific with local pain being by far the most common symptom. Occasionally a soft tissue mass may be palpable. Pathological fractures also occur. Systemic symptoms including fever may be present. ESR is also elevated.

Pathology

Ewing sarcoma is a small round blue cell tumour with regular sized primitive appearing cells. It is closely related to the soft tissue tumours pPNETAskin tumour and neuroepithelioma, which collectively are referred to as Ewing sarcoma family of tumours (ESFT) 1. They share not only microscopic appearances but also demonstrate a non-random t(11;22)(q24;q12) chromosome rearrangement. 

Location
  • lower limb: 45%
    • femur most common
  • pelvis: 20%
  • upper limb: 13%
  • spine and ribs: 13% (see thoracic Ewings sarcoma)
    • sacrococcygeal region most common 4
  • skull/face: 2%

Alternatively 3:

  • long bones: 50-60%
    • femur: 25%
    • tibia: 11%
    • humerus: 10%
  • flat bones: 40%

As far as location within long bones, the tumor is almost always metadiaphyseal or diaphyseal 2-3:

  • mid-diaphysis: 33%
  • metadiaphysis: 44%
  • metaphysis: 15%
  • epiphysis: 1-2%

Radiographic features

Ewing sarcomas tend to be large with poorly marginated tumours, with over 80% demonstrating extension into adjacent soft tissues. It should be noted that pPNET often extend into bone, making the distinction difficult.

Plain radiograph and CT

The appearance of these tumours is very variable, but they usually have clearly aggressive appearance. Common findings include 2:

They occasionally demonstrate other appearances, including Codman triangles, spiculated (sunburst) or thick periosteal reaction and even bone expansion or cystic components.

Soft tissue calcification is uncommon, seen in less than 10% of cases 2.

MRI
  • T1: low to intermediate signal
  • T1 C+ (Gd): heterogeneous but prominent enhancement
  • T2: heterogeneously high signal, may see hair on end low signal striations
Nuclear medicine

Ewing sarcomas demonstrate increased uptake on both Gallium67-citrate and all three phases of the Technetium99m methylene diphosphonate bone scans 6.

Treatment and prognosis

Systemic chemotherapy is the mainstay of treatment with surgery and/or radiotherapy playing a role depending on the location and size of the tumour.

What was once a uniformly fatal tumour now has respectable survival rates, although these vary with location. Spinal tumours for example have up to 86% long term survival compared to 25% of sacrococcygeal tumours 4. The overall 5 year survival is in the order of 50-75% of patients with local disease only at the time of presentation 5.

Prognosis is significantly impacted by the presence of distant metastases at the time of diagnosis, which is far more common for the pelvis (25-30%) compared to extremities (<10%) 5. Metastases most frequently go to bone or lungs.

History and etymology

It is named after James Stephen Ewing (1866-1943), an American pathologist, who first described his eponymous tumour in 1920 8,11.

Differential diagnosis

  • -<p><strong>Ewing sarcomas</strong> are the second most common malignant primary bone tumours of childhood after <a href="/articles/osteosarcoma">osteosarcoma</a>, typically arising from medullary cavity with invasion of the Haversian system. They usually present as moth-eaten destructive permeative lucent lesions in the shaft of long bones with large soft tissue component without osteoid matrix and typical onion skin periostitis. It may also involve flat bones and appears sclerotic in up to 30% of cases.</p><h4>Epidemiology</h4><p>Ewing sarcoma typically occurs in children and adolescents between 10 and 20 years of age (95% between 4 and 25 years of age), and has a slight male predilection (M:F 1.5:1) <sup>1,2</sup>.</p><p>The Ewing sarcoma family of tumors primarily occurs in white patients and is uncommon in blacks and Asians. In the United States, the incidence in Asians/Pacific Islanders is about one-half that in Caucasians, while the incidence among African Americans is one-ninth that in Caucasians <sup>12</sup>.</p><h4>Clinical presentation</h4><p>Presentation is non-specific with local pain being by far the most common symptom. Occasionally a soft tissue mass may be palpable. Pathological fractures also occur. Systemic symptoms including fever may be present. ESR is also elevated.</p><h4>Pathology</h4><p>Ewing sarcoma is a <a href="/articles/small-round-blue-cell-tumours">small round blue cell tumour </a>with regular sized primitive appearing cells. It is closely related to the soft tissue tumours <a href="/articles/ppnet">pPNET</a>, <a href="/articles/askin-tumour-1">Askin tumour</a> and <a href="/articles/neuroepithelioma">neuroepithelioma</a>, which collectively are referred to as <a href="/articles/ewing-sarcoma-family-of-tumours">Ewing sarcoma family of tumours</a> (ESFT) <sup>1</sup>. They share not only microscopic appearances but also demonstrate a non-random t(11;22)(q24;q12) chromosome rearrangement. </p><h5>Location</h5><ul>
  • +<p><strong>Ewing sarcomas</strong> are the second most common malignant primary bone tumours of childhood after <a href="/articles/osteosarcoma">osteosarcoma</a>, typically arising from medullary cavity with invasion of the Haversian system. They usually present as moth-eaten destructive permeative lucent lesions in the shaft of long bones with large soft tissue component without osteoid matrix and typical onion skin periostitis. It may also involve flat bones and appears sclerotic in up to 30% of cases.</p><h4>Epidemiology</h4><p>Ewing sarcoma typically occurs in children and adolescents between 10 and 20 years of age (95% between 4 and 25 years of age), and has a slight male predilection (M:F 1.5:1) <sup>1,2</sup>.</p><p>The Ewing sarcoma family of tumors primarily occurs in white patients. In the United States, the incidence in Asians/Pacific Islanders is about one-half that in Caucasians, while the incidence among African Americans is one-ninth that in Caucasians <sup>12</sup>.</p><h4>Clinical presentation</h4><p>Presentation is non-specific with local pain being by far the most common symptom. Occasionally a soft tissue mass may be palpable. Pathological fractures also occur. Systemic symptoms including fever may be present. ESR is also elevated.</p><h4>Pathology</h4><p>Ewing sarcoma is a <a href="/articles/small-round-blue-cell-tumours">small round blue cell tumour </a>with regular sized primitive appearing cells. It is closely related to the soft tissue tumours <a href="/articles/ppnet">pPNET</a>, <a href="/articles/askin-tumour-1">Askin tumour</a> and <a href="/articles/neuroepithelioma">neuroepithelioma</a>, which collectively are referred to as <a href="/articles/ewing-sarcoma-family-of-tumours">Ewing sarcoma family of tumours</a> (ESFT) <sup>1</sup>. They share not only microscopic appearances but also demonstrate a non-random t(11;22)(q24;q12) chromosome rearrangement. </p><h5>Location</h5><ul>

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.